# OnCo record prostate-hrr-eligibility (term). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/terms/prostate-hrr-eligibility/>
  a schema:DefinedTerm ;
  onco:kind "term" ;
  schema:identifier "prostate-hrr-eligibility" ;
  schema:name "Who is eligible for a PARP inhibitor in prostate cancer, and why the gene matters"@en ;
  schema:alternateName "HRR eligibility prostate"@en, "BRCA testing prostate cancer"@en, "PARP inhibitor eligibility prostate"@en ;
  schema:description "PARP inhibitors work in prostate cancer only for men whose tumour carries a fault in a DNA repair gene, and mostly only if that gene is BRCA1 or BRCA2. A fault in ATM, which is often reported on the same panel, does not seem to count."@en ;
  schema:url <https://onco.cc/terms/prostate-hrr-eligibility/> ;
  schema:dateModified "2026-09-25"^^xsd:date ;
  schema:citation <https://doi.org/10.1056/NEJMoa2214676>, <https://www.nice.org.uk/guidance/ta887>, <https://www.nice.org.uk/guidance/ta951>, <https://www.nice.org.uk/guidance/ta1130>, <https://www.nice.org.uk/guidance/terminated/ta1032> ;
  onco:status "established" ;
  onco:cancers <https://onco.cc/cancers/prostate/>, <https://onco.cc/cancers/prostate-mcrpc/> ;
  onco:technologies <https://onco.cc/technologies/parp-inhibitor/>, <https://onco.cc/technologies/germline-testing/> ;
  onco:targets <https://onco.cc/targets/brca/>, <https://onco.cc/targets/atm/>, <https://onco.cc/targets/parp/> ;
  onco:drugs <https://onco.cc/drugs/olaparib/>, <https://onco.cc/drugs/rucaparib/>, <https://onco.cc/drugs/niraparib/>, <https://onco.cc/drugs/talazoparib/> ;
  onco:terms <https://onco.cc/terms/hrd/>, <https://onco.cc/terms/castration-resistance/> ;
  onco:trials <https://onco.cc/trials/triton3/>, <https://onco.cc/trials/profound/>, <https://onco.cc/trials/propel/>, <https://onco.cc/trials/magnitude/>, <https://onco.cc/trials/talapro-2/> .